[1]王怡帆,常青,周英杰,等.特制接骨丸对椎间植骨融合术后患者腰椎间盘融合效果的影响[J].西部中医药,2025,38(12):98-103.[doi:10.12174/j.issn.2096-9600.2025.12.19]
　WANG Yifan,CHANG Qing,ZHOU Yingjie,et al.Effects of Special Bone-setting Pills on Lumbar Intervertebral Disc Fusion in Patients after Interbody Fusion[J].Western Journal of Traditional Chinese Medicine,2025,38(12):98-103.[doi:10.12174/j.issn.2096-9600.2025.12.19]
点击复制

特制接骨丸对椎间植骨融合术后患者腰椎间盘融合效果的影响()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年12期
页码:
98-103
栏目:
临床研究
出版日期:
2025-12-15

文章信息/Info

Title:
Effects of Special Bone-setting Pills on Lumbar Intervertebral Disc Fusion in Patients after Interbody Fusion
作者:
王怡帆1, 常青2, 周英杰2, 王孝辉2, 赵刚2
1.河南中医药大学，河南 郑州 450046
2.河南省骨科医院／河南省洛阳正骨医院，河南 洛阳 471002
Author(s):
WANG Yifan1, CHANG Qing2, ZHOU Yingjie2, WANG Xiaohui2, ZHAO Gang2
1.Henan University of Chinese Medicine, Zhengzhou 450046, China
2.Henan Provincial Orthopedic Hospital/Luoyang Orthopedic - Traumatological Hospital, Luoyang 471002, China
关键词:
腰椎间盘融合; 特制接骨丸; 血管内皮生长因子; 转化生长因子; 骨形态发生蛋白2; 骨修复
Keywords:
lumbosacral disc fusion; special bone-setting pills; VEGF; TGF-; BMP-2; bone repair
分类号:
R274.9
DOI:
10.12174/j.issn.2096-9600.2025.12.19
文献标志码:
B
摘要:
目的探讨特制接骨丸对椎间植骨融合术后患者椎间融合效果的临床作用。 方法将80例行椎间植骨融合术的患者按随机数字表法分为对照组和观察组，每组40例。对照组术后行常规治疗，观察组在对照组基础上口服特制接骨丸至术后6个月。比较两组围手术期参数（手术时间、术中出血量及术后使用止痛药的情况）。于术前，术后1周、3个月、6个月检测两组血清血管内皮生长因子（vascular endothelial growth factor，VEGF）、转化生长因子β1（transforming growth factor-β1，TGF-β1）、骨形态发生蛋白2（bone morphogenetic protein 2，BMP-2）水平；比较术前、术后6个月两组影像学椎间融合情况及视觉模拟评分（visual analogue scale，VAS）、Oswestry功能障碍指数（oswestry disability index，ODI）评分、日本骨科协会评分（Japanese orthopaedic association score，JOA）；比较两组不良反应。 结果两组围手术期参数比较，差异无统计学意义（P＞0.05）；治疗后，两组血清VEGF、TGF-β1水平均呈先升后降趋势（P＜0.05），BMP-2水平呈先降后升趋势（P＜0.05），且观察组各项指标的改善程度优于对照组（P＜0.05）；观察组影像学椎间融合情况及VAS、JOA、ODI评分的改善程度均优于对照组（P＜0.05）；两组均未出现不良反应。 结论特制接骨丸应用于椎间融合术后能有效提高椎间融合率，减轻患者疼痛症状，改善腰椎功能，其作用机制可能与调节VEGF、TGF-β1、BMP-2的表达水平有关。
Abstract:
ObjectiveTo explore clinical effects of special bone-setting pills on lumbar intervertebral disc fusion in patients after interbody fusion. MethodsEighty patients undergoing interbody fusion were allocated to the control group and the observation group according to random number table method with 40 cases in each. The control group received routine therapy after the operation, and the observation group orally took special bone-setting pills based on the control group till six months after the operation. To compare perioperative parameters (operation time, intraoperative blood loss and use of painkillers after surgery) between the two groups. To detect the levels of VEGF, TGF-β1, and BMP-2 in the two groups before the operation, one week, three and six months after the operation; and to compare imaging of intervertebral fusion, VAS and ODI scores, and JOA before the surgery and six months after the operation; and to compare adverse reaction between the two groups. ResultsThe difference had no statistical meaning in perioperative parameters between the two groups (P>0.05); after the treatment, the levels of VEGF and TGF-β1 showed a trend of rising first and then falling (P<0.05), the levels of BMP-2 presented a trend of falling first and then rising (P<0.05), and the improvements of the indexes of the observation group were better than these of the control group (P<0.05); the improvements of lumbosacral fusion, VAS, JOA and ODI scores of the observation group were superior to these of the control group (P<0.05); no adverse reactions happened in the two groups. ConclusionThe application of special bone-setting pills in patients after interbody fusion could effectively improve lumbar intervertebral disc fusion, relieve the patients’ pain and boost lumbar function, and its mechanism might be related to regulating the expressions of VEGF, TGF-β1 and BMP-2.

备注/Memo

备注/Memo:
洛阳市科技计划医疗卫生项目（1930002A）。王怡帆（1996—），男，硕士学位，医师。研究方向：脊柱疾病临床诊治及研究。
更新日期/Last Update: 2025-12-15